MedTrace Logo

Sulforaphane in Treating Patients With Recurrent Prostate Cancer

NCT01228084 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-04-28

Study results available
· View outcomes & findings →

Summary

This phase II trial studies how well sulforaphane works in treating patients with recurrent prostate cancer. Sulforaphane may prevent or slow the growth of certain cancers.

Conditions

  • Adenocarcinoma of the Prostate
  • Recurrent Prostate Cancer

Interventions

DRUG

Sulforaphane

Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.

OTHER

Laboratory biomarker analysis

Correlative studies

OTHER

Pharmacological study

Correlative studies

Sponsors & Collaborators

  • The Wayne D. Kuni and Joan E. Kuni Foundation

    collaborator OTHER

  • OHSU Knight Cancer Institute

    lead OTHER

Principal Investigators

  • Joshi J Alumkal, MD · OHSU Knight Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2012-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01228084 on ClinicalTrials.gov